您当前的位置：
首页 >
文章列表页 >
Research advances in EphA2-targeted theranostic radiopharmaceuticals
更新时间：2025-12-15

    • Research advances in EphA2-targeted theranostic radiopharmaceuticals

    • “Nuclear medicine molecular imaging technology plays a core role in the field of precision diagnosis and treatment of tumors, and progress has been made in the development of EphA2 targeted nuclear medicine molecular probes, providing new directions for tumor treatment.”
    • Oncoradiology   Vol. 34, Issue 5, Pages: 433-443(2025)

    • DOI：10.19732/j.cnki.2096-6210.2025.05.001    

      CLC：

    • Received：18 September 2025，

      Published Online：06 November 2025，

      Published：28 October 2025

    移动端阅览

  • Xinyu LIU, Xiaoping XU, Shaoli SONG. Research advances in EphA2-targeted theranostic radiopharmaceuticals[J]. Oncoradiology, 2025, 34(5): 433-443. DOI： 10.19732/j.cnki.2096-6210.2025.05.001.

  •  
  •  

0

Views

72

下载量

0

CNKI被引量

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

64Cu/177Lu-DOTA-diZD, a small-molecule-based theranostic pair for triple-negative breast cancer
FAPI in radionuclide theranostics: toward a new emerging paradigm for tumor management
The value of  68 Ga-FAP-2286 PET/CT in predicting the survival of patients with advanced digestive system malignant tumors after treatment
The current status and prospects of theranostic in targeted radionuclide therapy
The ground part of data acquisition system for carbon/oxygen well logging

Related Author

Yuqian HUANG
Wei FAN
Ying DING
Hui YANG
PEI Wenjie
ZHANG Yu
ZHANG Jintao
HUANG Zhanwen

Related Institution

Department of Nuclear Medicine, Sun Yat-sen University Cancer Centre
Department of Nuclear Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
Key Laboratory of Precision Diagnosis and Treatment in Oncology Nuclear Medicine for Henan Provincial
0